Evidence map›Paper›PMID 35648093›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy.

Fei Shu, Salman R Punekar, Vamsidhar Velcheti, Miguel F Sanmamed, Jun Wang

Open access · bronzeAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Fei ShuDepartment of Pathology, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.ORCID 0000-0002-5815-1907
Salman R PunekarThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.ORCID 0000-0002-7613-6305
Vamsidhar VelchetiThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.ORCID 0000-0002-6589-0759
Miguel F SanmamedProgram of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-7295-6074
Jun WangDepartment of Pathology, New York University Grossman School of Medicine, NYU Langone Health, New York, New York.ORCID 0000-0002-6346-2929
NYU Langone Health · USUniversidad de Navarra · ES

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
BLRD VA IK6 BX006185
6 · The paper itself

Abstract

4-1BB has been considered a promising target in cancer immunotherapy for decades. Nevertheless, early 4-1BB-targeted agents demonstrated significant liver immuno-toxicity. A new wave of 4-1BB-based therapy is being developed to circumvent hepatotoxicity with a bispecific molecule that directs 4-1BB agonism to the tumor microenvironment by targeting tumor-associated immune checkpoint molecule PD-L1. See related article by Peper-Gabriel et al., p. 3387.

Indexed as

B7-H1 AntigenNeoplasmsHumansImmunologic FactorsImmunotherapyTumor MicroenvironmentTumor Necrosis Factor Receptor Superfamily, Member 9B7-H1 AntigenImmunologic FactorsTumor Necrosis Factor Receptor Superfamily, Member 9

Identifiers

PMID35648093
OpenAlexW4282945728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.